ArticleScientific reports2025
Low expression of SGCA promotes lung squamous cell carcinoma malignant progression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung squamous cell carcinoma (LUSC) is a common type of non-small-cell lung cancer with high mortality, lacks effective diagnostic indicators and therapeutic targets. This study aims to reveal that low expression of Alpha-Sarcoglycan (SGCA) promotes LUSC progression and to provide a biomarker for its diagnosis, prognosis evaluation, and targeted therapy. TCGA data and 70 clinical LUSC patients were analyzed. In vitro, H520 and H1703 cells with overexpressed SGCA were transfected with pc-SGCA plasmids, and their proliferation, apoptosis, and invasion were examined. In vivo, a subcutaneous tumorigenic mouse model was constructed. SGCA was significant in diagnosing LUSC and negatively correlated with T stage. Low SGCA expression enhanced proliferation, invasion, and migration, and inhibited apoptosis. Overexpression of SGCA inhibited tumor growth in mice. Low expression of SGCA is closely associated with LUSC progression, making it a potential prognostic factor and therapeutic target for LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.